Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics Europese Unie - Nederlands - EMA (European Medicines Agency)

prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics

novartis vaccines and diagnostics s.r.l. - influenza-virus oppervlakte-antigenen (hemagglutinine en neuraminidase) van stam a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vaccins - actieve immunisatie tegen het h5n1-subtype van influenza a-virus. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Artuvetrin - test epithelia Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

artuvetrin - test epithelia

nextmune b.v. - epithelia allergenen - oplossing voor injectie - epithelia allergenen 100 µg/ml, - allergens - honden

Artuvetrin - therapie epithelia Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

artuvetrin - therapie epithelia

nextmune b.v. - epithelia allergenen - suspensie voor injectie - epithelia allergenen 100 µg/ml, - allergens - honden

Spikevax (previously COVID-19 Vaccine Moderna) Europese Unie - Nederlands - EMA (European Medicines Agency)

spikevax (previously covid-19 vaccine moderna)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccins - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Purevax RCPCh Europese Unie - Nederlands - EMA (European Medicines Agency)

purevax rcpch

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals voor felidae, - cats - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. onsets van immuniteit zijn aangetoond een week na de primaire vaccinatiekuur voor rhinotracheitis, calicivirus, chlamydophila felis en panleucopenie componenten. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Suvaxyn Aujeszky 783 + O/W Europese Unie - Nederlands - EMA (European Medicines Agency)

suvaxyn aujeszky 783 + o/w

zoetis belgium sa - levend verzwakt virus van de ziekte van aujeszky - immunologische - varkens - actieve immunisatie van varkens vanaf de leeftijd van 10 weken om de mortaliteit en klinische tekenen van de ziekte van aujeszky te voorkomen en de uitscheiding van het veldvirus van aujeszky te verminderen. passieve immunisatie van het nageslacht van gevaccineerde gelten en zeugen om mortaliteit en klinische tekenen van de ziekte van aujeszky te verminderen en de uitscheiding van het veldvirus van aujeszky te verminderen.

Zoonotic Influenza Vaccine Seqirus Europese Unie - Nederlands - EMA (European Medicines Agency)

zoonotic influenza vaccine seqirus

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vaccins - active immunisation against h5 subtype of influenza a virus.

Focetria Europese Unie - Nederlands - EMA (European Medicines Agency)

focetria

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - griepvaccins - profylaxe van influenza veroorzaakt door a (h1n1v) 2009-virus. focetria mag worden gebruikt in overeenstemming met officiële richtlijnen.

Theolair Retard 175, tabletten met gereguleerde afgifte 175 mg Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

theolair retard 175, tabletten met gereguleerde afgifte 175 mg

mylan healthcare b.v. krijgsman 20 1186 dm amstelveen - theofylline 0-water - tablet met verlengde afgifte - celluloseacetaatftalaat ; lactose 1-water ; magnesiumstearaat (e 470b), - theophylline

Theolair Retard 250, tabletten met gereguleerde afgifte 250 mg Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

theolair retard 250, tabletten met gereguleerde afgifte 250 mg

mylan healthcare b.v. krijgsman 20 1186 dm amstelveen - theofylline 0-water - tablet met verlengde afgifte - celluloseacetaatftalaat ; lactose 1-water ; magnesiumstearaat (e 470b), - theophylline